Next Article in Journal
Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye
Next Article in Special Issue
Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases
Previous Article in Journal
Effects of Surface Protein Adsorption on the Distribution and Retention of Intratumorally Administered Gold Nanoparticles
Previous Article in Special Issue
Therapeutic Ophthalmic Lenses: A Review
 
 
Article

Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography

1
Department of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain
2
Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), University of Zaragoza, 50009 Zaragoza, Spain
3
RETICS: Thematic Networks for Co-Operative Research in Health for Ocular Diseases, 28040 Madrid, Spain
4
Biomaterials Group, Aragon Institute of Engineering Research (I3A), University of Zaragoza, 50018 Zaragoza, Spain
5
Department of Mechanical Engineering, University of Zaragoza, 50018 Zaragoza, Spain
6
Department of Pathology, Lozano Blesa University Hospital, 50009 Zaragoza, Spain
7
Institute for Chemical Synthesis and Homogeneous Catalysis (ISQCH), Faculty of Sciences, University of Zaragoza-CSIC, C/Pedro Cerbuna 12, 50009 Zaragoza, Spain
8
Chromatography and Spectroscopy Laboratory, Institute for Chemical Synthesis and Homogeneous Catalysis (ISQCH), Faculty of Sciences, University of Zaragoza-CSIC, Pedro Cerbuna 12, 50009 Zaragoza, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Anuj Chauhan
Pharmaceutics 2021, 13(2), 217; https://doi.org/10.3390/pharmaceutics13020217
Received: 30 November 2020 / Revised: 27 January 2021 / Accepted: 2 February 2021 / Published: 5 February 2021
(This article belongs to the Special Issue Recent Advances in Ophthalmic Drug Delivery)
Intravitreal injection is the gold standard therapeutic option for posterior segment pathologies, and long-lasting release is necessary to avoid reinjections. There is no effective intravitreal treatment for glaucoma or other optic neuropathies in daily practice, nor is there a non-invasive method to monitor drug levels in the vitreous. Here we show that a glaucoma treatment combining a hypotensive and neuroprotective intravitreal formulation (IF) of brimonidine–Laponite (BRI/LAP) can be monitored non-invasively using vitreoretinal interface imaging captured with optical coherence tomography (OCT) over 24 weeks of follow-up. Qualitative and quantitative characterisation was achieved by analysing the changes in vitreous (VIT) signal intensity, expressed as a ratio of retinal pigment epithelium (RPE) intensity. Vitreous hyperreflective aggregates mixed in the vitreous and tended to settle on the retinal surface. Relative intensity and aggregate size progressively decreased over 24 weeks in treated rat eyes as the BRI/LAP IF degraded. VIT/RPE relative intensity and total aggregate area correlated with brimonidine levels measured in the eye. The OCT-derived VIT/RPE relative intensity may be a useful and objective marker for non-invasive monitoring of BRI/LAP IF. View Full-Text
Keywords: brimonidine; Laponite; drug delivery; glaucoma; nanomedicine; monitoring; optical coherence tomography; vitreous; intravitreal brimonidine; Laponite; drug delivery; glaucoma; nanomedicine; monitoring; optical coherence tomography; vitreous; intravitreal
Show Figures

Graphical abstract

MDPI and ACS Style

Rodrigo, M.J.; Palomar, A.P.d.; Montolío, A.; Mendez-Martinez, S.; Subias, M.; Cardiel, M.J.; Martinez-Rincon, T.; Cegoñino, J.; Fraile, J.M.; Vispe, E.; Mayoral, J.A.; Polo, V.; Garcia-Martin, E. Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography. Pharmaceutics 2021, 13, 217. https://doi.org/10.3390/pharmaceutics13020217

AMA Style

Rodrigo MJ, Palomar APd, Montolío A, Mendez-Martinez S, Subias M, Cardiel MJ, Martinez-Rincon T, Cegoñino J, Fraile JM, Vispe E, Mayoral JA, Polo V, Garcia-Martin E. Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography. Pharmaceutics. 2021; 13(2):217. https://doi.org/10.3390/pharmaceutics13020217

Chicago/Turabian Style

Rodrigo, Maria Jesus, Amaya Pérez del Palomar, Alberto Montolío, Silvia Mendez-Martinez, Manuel Subias, Maria Jose Cardiel, Teresa Martinez-Rincon, José Cegoñino, José Maria Fraile, Eugenio Vispe, José Antonio Mayoral, Vicente Polo, and Elena Garcia-Martin. 2021. "Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography" Pharmaceutics 13, no. 2: 217. https://doi.org/10.3390/pharmaceutics13020217

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop